Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations
A pooled analysis of randomized clinical trials

Bi-Cheng Wang, MDa,b, Bo-Hua Kuang, MDa, Xin-Xiu Liu, MDa, Guo-He Lin, MDb

Abstract

Background: Non-small-cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutant occurs in 3% of NSCLCs. Targeted agents for this population remain an unmet need. In this analysis, we pooled-analyzed the efficacy and safety of poziotinib, a novel tyrosine kinase inhibitor, in HER2 exon 20 mutant NSCLC.

Methods: PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were systematically searched on March 9, 2022. The primary endpoints were objective response rate (ORR) and disease control rate. The secondary endpoint was treatment-related adverse events.

Results: Three prospective clinical trials, involving 126 patients, were identified. The pooled ORR and disease control rate of poziotinib in HER2 exon 20 mutant NSCLC were 27% (95% CI, 19–35) and 72% (95% CI, 64–80), respectively. Patients with G778_P780dupGSP had the highest ORR (88%; 95% CI, 33–100; n = 12), followed by Y772_A775dupYVMA (20%; 95% CI, 12–30; n = 88) and G776delinsVC (19%; 95% CI, 0–50; n = 13). The most common grade 3 to 4 treatment-related adverse events were skin rash (36%), diarrhea (23%), and oral mucositis (13%).

Conclusion: Poziotinib demonstrates moderate antitumor activity in previously treated HER2 exon 20 mutant NSCLC patients with a manageable safety profile. In addition, different subgroup mutations show various benefits of poziotinib treatment. Large-scale and multiarm clinical trials are warranted to confirm a suitable population and therapeutic strategies.

Abbreviations: DCR = disease control rate, HER2 = human epidermal growth factor receptor 2, NSCLC = non-small-cell lung cancer, ORR = objective response rate, PFS = progression-free survival, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses, T-DXd = trastuzumab deruxtecan, TRAE = treatment-related adverse events.

Keywords: HER2 exon 20 mutant, non-small-cell lung cancer, pooled analysis, poziotinib

1. Introduction

Currently, the standard of care for non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations is chemotherapy with or without immunotherapy.[1,2]

In the National Comprehensive Cancer Network guideline for NSCLC, ado-trastuzumab emtansine and trastuzumab deruxtecan (T-DXd) have been suggested as treatment options for patients with HER2 mutation-positive metastatic NSCLC.[3] In a study of ado-trastuzumab emtansine, the partial response rate was 44%, and no patients stopped treatment due to toxicity or death.[4] In a phase 2 trial of T-DXd (DESTINY-Lung01 trial), the results showed a 55% objective response rate (ORR) in HER2-mutated NSCLC patients; the median progression-free survival (PFS) and median overall survival were 8.2 months and 17.8 months, respectively.[5] Accordingly, anti-HER2 therapy could be an effective therapeutic strategy for HER2 exon 20 mutant NSCLC.

Poziotinib is a novel, irreversible, and covalent tyrosine kinase inhibitor that is small and flexible. Since the exon 20 mutant could sterically hinder the binding of drug-binding pocket and third-generation inhibitors, poziotinib overcomes this hindrance.[6] Although poziotinib is currently only available at the stage of clinical trial, the regimen showed an ORR of approximately 27% in advanced NSCLC patients harboring HER2 mutations, which was similar to the efficacy of trastuzumab plus pertuzumab plus docetaxel combination therapy (29%).[7–9] Additionally, different HER2 mutation types, including Y772_A775dupYVMA, G778_P780dupGSP, and G776delinsVC, displayed different therapeutic responses.

Therefore, to better understand the application of poziotinib in patients with HER2 exon 20 mutant NSCLC and provide more useful information for clinicians and future explorations, we comprehensively synthesized the benefits and risks of poziotinib in published prospective clinical trials.
2. Methods
This study was conducted according to the preferred reporting items for systematic reviews and Meta-analyses guideline. The data used in the analysis were not original raw data but were based on published clinical studies with ethical approval. Therefore, ethical approval was not necessary.

2.1. Search strategy
We performed a comprehensive search in PubMed, Embase, Web of Science, and Cochrane CENTRAL of Controlled Trials databases. The search terms included: (non small cell lung cancer) AND (epidermal growth factor receptor OR EGFR OR human epidermal growth factor 2 OR HER2 OR HER-2 OR Erb-B2 Receptor Tyrosine Kinase 2 OR ERBB2) AND (Exon 20) AND (Poziotinib OR HM781-36B OR NOV120101) on March 9, 2022. References of relevant published clinical trials and review articles were searched for additional eligible studies.

The inclusion criteria were as follows: NSCLC patients with HER2 exon 20 mutations were eligible; patients were treated with poziotinib; data on responses and treatment-related adverse events (TRAEs) were available; prospective studies. B.W. and B.K. independently performed the literature search. 2 of us (B.W. and G.L.) conducted the study selection. Discrepancies were resolved through consensus.

2.2. Outcome measures and data extraction
The primary outcomes were ORR and disease control rate (DCR). The secondary outcome was the incidence of TRAEs.

Data extraction was conducted by B.W. and B.K. independently and reviewed by G.L. Data regarding the 1st author, sample size, study design, proportion of female, dosing schedule, survival outcomes, responses, and number of TRAEs were collected.

2.3. Statistical analysis
R Studio (version 1.4.1717, R Foundation for Statistical Computing) was used to perform the statistical analyses. The “meta” package was used to conduct the fixed effect and random-effects meta-analyses for heterogeneity (I^2 and r). A random-effects model was selected when I^2 was > 50%. Otherwise, a fixed-effects model was used. Pooled proportions were estimated via the metaprop function in the “meta” package, applying a logit transformation and continuity correction of 0.5 and other default settings. Publication bias was assessed using funnel plots.

3. Results
3.1. Eligible studies and characteristics
A literature search identified 137 relevant records. 50 duplicate records were excluded. 59 full articles were remained for further assessment after title and abstract screening. Another 56 articles were excluded due to conference abstracts (n = 24), reviews (n = 16), case reports (n = 4), news/comments/letters (n = 3), basic researches (n = 3), protocols (n = 3), duplicated data (n = 2), and retrospective study (n = 1). Finally, 3 prospective clinical trials involving 126 patients were enrolled (Fig. 1).[7,8,12]

Table 1 depicts the patients and study characteristics. All eligible studies were open-label, phase 2 trials and published between 2018 and 2022. 68% of patients were female and 98% were adenocarcinoma. HER2 mutation types comprised G776 > VC, A775_G776insYVMA, E812K, Y772_A775dupYVMA, G778_P780dupGSP, and G776delinsVC. Two trials reported median PFS and duration of response (DoR). The median PFS was 5.5 months and the median DoR was nearly 5.0 months.

Figure 1. Flow diagram of the analysis.
Table 1

| Study | Year of Publication | Design | Trial number | Sample size | Female | Median age (range) | Median number of lines of prior therapies (range) | Median number of prior therapies D0 | Median PFS (range) | Median number of prior lines of therapies D0 | Median number of prior therapies D1 | Median number of prior lines of therapies D1 | Median number of prior therapies D2 | Median number of prior lines of therapies D2 | Median number of prior therapies D3 | Median number of prior lines of therapies D3 | Median number of prior therapies D4 | Median number of prior lines of therapies D4 | Median number of prior therapies D5 | Median number of prior lines of therapies D5 |
|-------|---------------------|--------|--------------|-------------|--------|-------------------|-----------------------------------------------|-------------------------------|-----------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| In-Jae | 2018                | A multicenter, open-label, phase 2 trial | NCT02993921 | 6            | 100%   | 60                | 30                                           | 60                            | 60              | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            |
| Oh     | 2019                | A single-center, open-label, phase 2 trial | NCT0103062006 | 30           | 73%    | 60                | 60                                           | 60                            | 60              | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            |
| Yasir Y. | 2017               | single-arm, open-label, phase 2 trial | NCT03813802 | 90           | 64%    | 60                | 60                                           | 60                            | 60              | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            |
| Xiuning | 2022               | A single-arm, open-label, phase 2 trial | NCT03318939 | 90           | 64%    | 60                | 60                                           | 60                            | 60              | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            |
| Le     | 2018                | A single-arm, phase 2 trial | NCT01616621 | 6            | 100%   | 60                | 60                                           | 60                            | 60              | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            | 60                                            |

Data of ORR and DCR were available from all enrolled patients (Fig. 2).[7,8,10] The pooled ORR and DCR were 27% (95% CI, 19-35; Heterogeneity: I² = 0%, P = .92) and 72% (95% CI, 64-80; Heterogeneity: I² = 0%, P = .85), respectively.

In addition, 3 subtypes of HER2 exon 20 mutations were analyzed (Fig. 3).[7,8] In the Y772_A775dupYVMA subgroup, the integrated ORR was 20% (95% CI, 12-30; Heterogeneity: I² = 0%, P = .81). 12 patients enrolled in the G778_P780dupGSP subgroup had an ORR of 88% (95% CI, 33-100; Heterogeneity: I² = 71%, P = .06). For the 13 patients with G776delinsVC mutation, the integrated ORR was 19% (95% CI, 0-50; Heterogeneity: I² = 0%, P = .45).

4.1. Treatment-related adverse events

A comprehensive list of the incidences of all grade and grade 3 to 4 diarrhea, skin rash, oral mucositis, paronychia, dry skin, nausea, alopecia, pruritus, vomiting, and weight loss is provided in Tables 2 and 3.

The most common all grade TRAE was diarrhea (82%; 95% CI, 74-89), followed by skin rash (74%; 95% CI, 42-97), oral mucositis (68%; 95% CI, 40-79), paronychia (53%; 95% CI, 22-82), and dry skin (46%; 95% CI, 17-77) (Table 2).

The most common grade 3 to 4 TRAEs (top 5) were skin rash (36%; 95% CI, 15-60), diarrhea (23%; 95% CI, 15-31), oral mucositis (13%; 95% CI, 3-29), paronychia (7%; 95% CI, 0-35), and pruritus (3%; 95% CI, 0-7) (Table 3).

4.2. Publication bias

Figure 4 showed the funnel plots of ORR and DCR, and no publication bias was found in the analyses.

5. Discussion

In this pooled analysis, poziotinib resulted in 27% ORR and 72% DCR in NSCLC patients with HER2 exon 20 mutation. The most common all grade and grade 3 to 4 TRAEs were diarrhea and skin rash, respectively. Based on our results, poziotinib exhibited moderate efficacy in HER2 exon 20 mutant NSCLC. One important reason is that only two participants received poziotinib as a first-line therapy and most of the participants had been previously treated with chemotherapy, immunotherapy, or other HER2-targeted therapy.

In cohort 4 of the ZENITH20 trial, 48 newly diagnosed NSCLC patients with HER2 exon 20 mutations treated with poziotinib showed meaningful effects with an ORR of 44% and a DCR of 75%.[13] Accordingly, patients might benefit more from first-line poziotinib therapy. A retrospective study reported the responses to poziotinib in 8 HER2 exon 20 mutant NSCLC patients in the real world.[14] Four patients experienced a partial response, and 3 experienced stable disease with an ORR of 50% from first-line poziotinib therapy. A retrospective study reported the responses to poziotinib in 8 HER2 exon 20 mutations treated with poziotinib as a first-line therapy and most of the participants had been previously treated with chemotherapy, immunotherapy, or other HER2-targeted therapy.

Subsequently, we found that the mutation types in each study were different. Whether different mutation types respond differently to poziotinib treatment remains unclear. In the enrolled trials, at least six HER2 exon 20 mutation types were recorded. Three types of patients were eligible for subgroup analysis. The G778_P780dupGSP group showed the highest ORR (88%). Considering that the number of patients was only 12, we suggest that future detection can focus on HER2 exon 20 mutation types in the poziotinib treatment.

Dose reduction during the poziotinib treatment is another issue that deserves our attention. 86% of patients reduced
Figure 2. Forest plots of the objective response rate (A) and disease control rate (B) of poziotinib in treating HER2 exon 20 mutant non-small-cell lung cancer. HER2 = human epidermal growth factor receptor 2.

Figure 3. Forest plots of the objective response rates for the subgroup analysis of HER2 exon 20 mutations. (A) Y772_A775dupYVMA; (B) G778_P780dupGSP; (C) G776delinsVC. HER2 = human epidermal growth factor receptor 2.
Table 2
Incidences of all grade adverse events.

| Adverse event | Incidence (95% CI) |
|---------------|-------------------|
| Diarrhea      | 82% (74–89)       |
| Skin rash     | 74% (42–97)       |
| Oral mucositis| 68% (40–79)       |
| Paronychia    | 53% (22–82)       |
| Dry skin      | 46% (17–77)       |
| Nausea        | 28% (20–36)       |
| Alopecia      | 27% (20–36)       |
| Pruritus       | 25% (17–33)       |
| Vomiting      | 22% (15–30)       |
| Weight loss   | 16% (10–24)       |

Table 3
Incidences of grade 3–4 adverse events.

| Adverse event | Incidence (95% CI) |
|---------------|-------------------|
| Skin rash     | 36% (15–60)       |
| Diarrhea      | 23% (15–31)       |
| Oral mucositis| 13% (3–29)        |
| Paronychia    | 7% (0–35)         |
| Pruritus       | 3% (0–7)          |
| Dry skin      | 2% (0–10)         |
| Nausea        | 1% (0–5)          |
| Vomiting      | 1% (0–7)          |
| Weight loss   | 1% (0–5)          |
| Alopecia      | 0                 |

Figure 4. Funnel plot of the objective response rate (A) and disease control rate (B).
the starting dose in In-Jae Oh’s trial (starting dose: 12 mg); 73% of patients had at least 1 dose reduction in the study by Yasir Y. Elamin (starting dose: 16 mg); 77% of patients in the study by Xiuning Le (starting dose: 16 mg) had experienced dose reduction. The primary reason for dose reduction of poziotinib is the side-effect profile, including treatment-related grade 3 to 4 skin rash, diarrhea, oral mucositis, and paronychia. Therefore, facing this dilemma and enhancing tolerability may make patients benefit more from poziotinib. Moreover, patients have often experienced dose reduction of tyrosine kinase inhibitors (afatinib, erlotinib, etc.) in clinical practice. As long as poziotinib is not discontinued permanently, we consider that this level of dose reduction is fully acceptable.

Additionally, trastuzumab combined with pertuzumab is superior to trastuzumab plus placebo in treating HER2 positive breast cancer patients. Based on the clinical experiences of HER2 positive breast cancer patients, combining 2 anti-HER2 drugs (e.g., poziotinib plus T-DXd) might be a novel strategy for NSCLC patients with HER2 exon 20 mutants.

6. Limitations

Two limitations in the analysis should be mentioned. First, the sample size was small because only 3 published studies were available. Second, the results of subgroup analysis of HER2 mutation types require more evidence.

7. Conclusions

Poziotinib is an effective treatment option for NSCLC patients with HER2 exon 20 mutations. Finding a suitable subgroup population and exploring new therapeutic strategies (e.g., combining chemotherapy and adjuvant poziotinib therapy) could be considered directions for future studies.

Acknowledgements

We thank the SNOWELL studio for helping to provide statistical support and improve the language.

Author contributions

Conceptualization: Bi-Cheng Wang.
Data curation: Bi-Cheng Wang, Bo-Hua Kuang.
Formal analysis: Bi-Cheng Wang.
Funding acquisition: Bi-Cheng Wang.
Investigation: Bi-Cheng Wang, Guo-He Lin.
Methodology: Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin.
Project administration: Bi-Cheng Wang, Guo-He Lin.
Resources: Bi-Cheng Wang, Guo-He Lin.
Software: Bi-Cheng Wang.
Supervision: Bi-Cheng Wang, Bo-Hua Kuang, Xin-Xiu Liu.
Validation: Bi-Cheng Wang, Xin-Xiu Liu.
Visualization: Bi-Cheng Wang, Xin-Xiu Liu.
Writing – original draft: Bi-Cheng Wang, Bo-Hua Kuang, Xin-Xiu Liu, Guo-He Lin.
Writing – review & editing: Bi-Cheng Wang, Bo-Hua Kuang, Xin-Xiu Liu, Guo-He Lin.

References

[1] Mazieres J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27:281–6.
[2] Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry. Ann Oncol. 2019;30:1321–8.
[3] Ettinger DS, Wood DE, Asnner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19:254–66.
[4] Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7.
[5] Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241–51.
[6] Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24:638–46.
[7] Elamin YY, Robichaux JP, Carter BW, et al. Poziotinib for patients with HER2 Exon 20 mutant non-small-cell lung cancer: results from a phase II trial. J Clin Oncol. 2022;40:702–9.
[8] Le X, Cornelissen R, Garassino M, et al. Poziotinib in non-small-cell lung cancer harboring HER2 Exon 20 insertion mutations after prior therapies: ZENITH20-2 trial. J Clin Oncol. 2022;40:710–8.
[9] Mazieres J, Lafitte C, Ricordel C, et al. Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial. J Clin Oncol. 2022;40:719–28.
[10] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.
[11] Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60.
[12] Oh IJ, Hur JY, Park CK, et al. Clinical activity of Pan-HER inhibitors against HER2-mutant lung adenocarcinoma. Clin Lung Cancer. 2018;19:e775–81.
[13] Cornelissen R, Sun S, Wollner M, et al. LBA46 efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: a multinational phase II study. J Clin Oncol. 2021;39:S1324.
[14] Prelaj A, Böttiglieri A, Proto C, et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program. Eur J Cancer. 2021;149:235–48.
[15] Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY phase 3 randomized clinical trial. JAMA Oncol. 2020;6:e2193692.